Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Mucopolysaccharidosis type IIIC (MPSIIIC) is a severe, rare autosomal recessive disorder caused by variants in the heparan-α-glucosaminide N-acetyltransferase (HGSNAT) gene which result in lysosomal accumulation of heparan sulfate. We analyzed clinical presentation, molecular defects and their haplotype context in 78 (27 novel) MPSIIIC cases from 22 countries, the largest group studied so far. We describe for the first time disease-causing variants in the patients from Brazil, Algeria, Azerbaijan, and Iran, and extend their spectrum within Canada, Colombia, Turkey, and the USA. Six variants are novel: two missense, c.773A>T/p.N258I and c.1267G>T/p.G423W, a nonsense c.164T>A/p.L55*, a splice-site mutation c.494-1G>A/p.[P165_L187delinsQSCYVTQAGVRWHHLGSLQALPPGFTPFSYLSLLSSWNC,P165fs], a deletion c.1348delG/p.(D450fs) and an insertion c.1479dupA/p.(Leu494fs). The missense HGSNAT variants lacked lysosomal targeting, enzymatic activity, and likely the correct folding. The haplotype analysis identified founder mutations, p.N258I, c.525dupT, and p.L55* in the Brazilian state of Paraiba, c.493+1G>A in Eastern Canada/Quebec, p.A489E in the USA, p.R384* in Poland, p.R344C and p.S518F in the Netherlands and suggested that variants c.525dupT, c.372-2G>A, and c.234+1G>A present in cis with c.564-98T>C and c.710C>A rare single-nucleotide polymorphisms, have been introduced by Portuguese settlers in Brazil. Altogether, our results provide insights into the origin, migration roots and founder effects of HGSNAT disease-causing variants, and reveal the evolutionary history of MPSIIIC.

Download full-text PDF

Source
http://dx.doi.org/10.1002/humu.23752DOI Listing

Publication Analysis

Top Keywords

mucopolysaccharidosis type
8
type iiic
8
evolutionary history
8
disease-causing variants
8
variants
6
molecular characterization
4
characterization large
4
large group
4
group mucopolysaccharidosis
4
iiic patients
4

Similar Publications

Objective: Laronidase is the first drug of enzyme replacement therapy approved for the treatment of mucopolysaccharidosis type I (MPS I). However, its adverse events (AEs) have not been investigated in real - world settings. The aim of this study was to investigate AEs associated with laronidase using the Food and Drug Administration Adverse Event Reporting System (FAERS).

View Article and Find Full Text PDF

Sleep disorder assessment in children and adolescents with neurodevelopmental disorders.

J Pediatr (Rio J)

September 2025

Escola de Medicina da Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil; Instituto do Cérebro (InsCer), Porto Alegre, RS, Brazil. Electronic address:

Objective: To review the associations between various neurodevelopmental disorders and the most prevalent sleep disorders in children and adolescents, focusing on clinical characteristics and diagnostic approaches.

Data Sources: A literature review was conducted using the PubMed database, employing the search terms "neurodevelopmental disorders" and "sleep disorders," including "insomnia," "sleep-related breathing disorders," "circadian rhythm sleep-wake disorders," "sleep-related movement disorders," "parasomnias," and "central disorders of hypersomnolence." Specific diagnostic terms related to neurodevelopmental and sleep disorders were also utilized.

View Article and Find Full Text PDF

Background: Mucopolysaccharidosis type II (MPS II) is a chronic inherited disease with multiorgan involvement, a progressive course, and restricted life expectancy.

Aim: To evaluate the predictors of fatal outcomes in MPS II patients.

Methods: In the retrospective cohort study, the clinical, laboratory data and enzyme replacement therapy (ERT) (84.

View Article and Find Full Text PDF

Prevalence of lysosomal storage disease (LSD) in Malaysia.

Malays J Pathol

August 2025

Inborn Errors of Metabolism & Genetics Unit, NMCRC, Institute for Medical Research, National Institutes of Health (NIH), Ministry of Health Malaysia, Selangor, Malaysia.

Lysosomal storage disorders (LSD) are storage disorders involving the malfunction of degradation enzymes in the lysosome. This study aimed to calculate the birth prevalence and carrier frequency of LSDs in the Malaysian population, to compare our results with previously reported epidemiologic data from other populations, and to describe the mutation spectrum in Malaysia. Between 2008 and 2017, 2.

View Article and Find Full Text PDF

Background: Lysosomal storage diseases (LSDs) is a large group of genetically heterogeneous inherited metabolic disorders that affect the functions of the lysosomes in various human tissues. Mucopolysaccharidosis type IIIA (MPSIIIA), Sanflippo syndrome A, is a rare autosomal recessive LSD caused by biallelic variants in the SGSH gene, codes for the lysosomal enzyme heparan-N-sulphatase. This study aimed to find out the SGSH mutational spectrum, clinical and biochemical characteristics in a cohort of MPS IIIA Egyptian patients.

View Article and Find Full Text PDF